国产多西他赛联合顺铂治疗晚期非小细胞肺癌疗效观察

Combined domestic docetaxel and cisplatin in treatment of advanced non-small-cell lung cancer(NSCLC)

目的观察国产多西他赛联合顺铂(DDP)治疗晚期非小细胞肺癌的近期疗效、临床受益和毒副反应。方法70例晚期NSCLC患者给予DP方案化疗:国产多西他赛75mg/m2,静滴,d1;顺铂75mg/m2,静滴,d1;21d为1周期。每例患者治疗2周期以上。结果全组完全缓解2例,部分缓解29例,稳定36例,进展3例,总有效率44.3%。中位生存期10.1个月,1年生存率38.6%(27/70)。临床受益疗效:行为状态阳性率51.4%,体重阳性率47.1%。毒副反应主要为骨髓抑制,脱发和消化系统反应。其中白细胞减少占75.7%,G-CSF治疗后较快恢复。结论国产多西他赛联合顺铂无论一线还是二线治疗晚期NSCLC近期疗效和临床受益良好,毒副反应可耐受。

Objective To investigate the therapeutic efficacy and toxicity of combination chemotherapy with domestic docetaxel and cisplatin in advanced non-small-cell lung cancer （NSCLC）. Methods All patients received domestic docetaxe175 mg/m^2 and cispl- atin 75 mg/m^2 on day 1. Repeated dosage was given every 3 weeks. Efficacy and toxicity were recorded in every 2 cycles. Results ALL patients were assessed for efficacy. Among 70 patients, CR was 2.9% （2/70）, PR was 41.4% （29/70）, SD was 51.4% （36/70）, PD was 4. 3% （3/70）. The overall response rate was 44.3%, the median survival rate was 10. 1 months and 1 year survival rate was 38.6%. Clinical benefit response： masculine rate of action estate and avoirdupois were 51.4% and 47. 1%. The main toxicities included myelosuppression, alopecia and vomiting. Hypolekocytosis was 75.7%. Conclusion The combination chemotherapy with domestic docetaxel and cisplatin in treating advanced NSCLC is effective and well-tolerated.